Tvardi Therapeutics, Inc.
TVRD
$3.02
$0.020.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.21M | -23.65M | -23.63M | -34.77M | -29.40M |
| Total Depreciation and Amortization | 95.00K | 95.00K | 95.00K | 95.00K | 95.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.89M | -4.15M | -4.39M | 7.79M | 2.36M |
| Change in Net Operating Assets | 508.00K | 5.06M | 2.88M | 5.04M | 8.64M |
| Cash from Operations | -23.50M | -22.65M | -25.05M | -21.86M | -18.31M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -10.08M | -15.08M | -20.43M | -10.88M | -- |
| Cash from Investing | -10.08M | -15.08M | -20.43M | -10.88M | -- |
| Total Debt Issued | -- | 28.30M | 28.30M | 28.30M | 28.30M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 532.00K | 531.00K | 424.00K | 3.00K | 5.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 22.17M | 20.88M | 21.30M | -2.91M | -1.30M |
| Cash from Financing | 22.70M | 49.71M | 50.02M | 25.39M | 27.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.88M | 11.98M | 4.54M | -7.35M | 8.70M |